Pharmacovigilance is one of the most deadline-driven disciplines in all of pharmaceuticals. A serious unexpected adverse reaction that meets expedited reporting criteria must reach the FDA or EMA within 7 or 15 calendar days of the company's awareness date — and missing that window is a regulatory violation with direct legal and reputational consequences for the sponsor and their PV service provider.
For pharmacovigilance consulting firms managing safety surveillance obligations for multiple pharmaceutical clients simultaneously, the administrative infrastructure behind that compliance is extensive. Case intake from multiple source channels, triage for seriousness and expectedness, deadline assignment, case processing coordination, and final submission tracking all have to happen in parallel across dozens or hundreds of active cases. When that coordination fails, safety scientists spend time on administrative follow-up instead of medical assessment, and deadlines slip.
A pharmacovigilance consulting virtual assistant addresses the intake and tracking layer of that workflow directly.
Adverse Event Case Intake: Managing Multiple Source Channels
Adverse event reports arrive through multiple channels: spontaneous reports from healthcare professionals and patients, literature cases identified through systematic search, clinical trial safety events reported by study sites, and regulatory authority queries. Each channel has its own format, and each case has to be logged, date-stamped with the date of first awareness, triaged for initial seriousness assessment, and assigned to a case processor.
A PV virtual assistant manages the intake queue across all source channels. They receive incoming reports — via dedicated safety email inboxes, safety contact forms, or direct forwarding from client safety teams — log each case in the safety database (Argus Safety, Aris G, or Oracle Empirica are common platforms), assign an initial triage classification based on the firm's defined criteria, and alert the responsible safety scientist that a new case is ready for medical review.
The VA also conducts duplicate searches to identify whether an incoming report matches a case already in the database — a step that prevents double-counting and keeps case series analysis accurate. Literature surveillance cases require an additional step: the VA logs the bibliographic reference, confirms the adverse event terminology matches MedDRA coding conventions, and flags the case for medical literature assessment.
Expedited Report Deadline Tracking: The Non-Negotiable Calendar
Once a case is classified as potentially expeditable — meaning it may meet criteria for a 7-day or 15-day ICSRs (Individual Case Safety Reports) submission to one or more health authorities — the clock starts. The VA's role is to ensure that every case with an open expedited deadline is visible, assigned, and progressing at a pace consistent with on-time submission.
The VA maintains a daily deadline tracker — typically in a shared spreadsheet or within the safety system's workflow module — showing every open expeditable case, its awareness date, its target submission date, its current processing status, and the responsible processor and reviewer. Each morning, the VA sends a prioritized task list to the case processing team, highlighting cases due within 48 hours and any cases that have not been updated in the expected processing window.
When a case is submitted to a health authority portal — FDA's MedWatch Plus, EudraVigilance, or a national competent authority system — the VA logs the submission confirmation number, the date and time of submission, and any acknowledgment received, and updates the master tracking file with the completed submission record.
Managing Client-Specific Reporting Obligations
PV consulting firms typically serve clients in multiple markets, each with distinct regulatory requirements. A medicinal product marketed in the EU, the US, Japan, and Canada may have four different ICSR submission formats and four different deadline frameworks. The VA maintains a client-specific obligation matrix — a reference document showing the applicable regulations, deadline windows, and submission portals for each product and market combination — and uses it as the source of truth for deadline assignment.
This matrix also supports periodic aggregate report scheduling: PSURs, PADERs, and DSURs all have defined submission windows that the VA calendars and flags to the responsible medical writer and safety lead well in advance.
If your pharmacovigilance firm needs systematic support for adverse event intake and expedited deadline tracking, Stealth Agents provides virtual assistants experienced in PV operations workflows.
Sources
- U.S. Food and Drug Administration. "Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines." FDA.gov, 2023.
- European Medicines Agency. "EudraVigilance — Individual Case Safety Report (ICSR) Processing." EMA.europa.eu, 2024.
- ICH Harmonised Guideline E2B(R3): Electronic Transmission of Individual Case Safety Reports. International Council for Harmonisation, 2023.